id	keyword
admet-337	patients
admet-337	et al
admet-337	egfr
admet-337	alk
admet-337	cancer
admet-337	nsclc
admet-337	crizotinib
admet-337	phase
admet-337	erlotinib
admet-337	cns
admet-337	resistance
admet-337	tki
admet-337	oncol
admet-337	dose
admet-337	drug
admet-337	kinase
admet-337	gefitinib
admet-337	mutations
admet-337	cell
admet-337	alectinib
admet-337	afatinib
admet-337	disease
admet-337	treatment
admet-337	months
admet-337	response
admet-337	study
admet-337	osimertinib